EU greenlights Cardima's surgical ablation probe for AF
Medical device company Cardima has received CE mark with an indication for surgical treatment of atrial fibrillation (AF) for marketing its surgical ablation probe, a component of its surgical ablation system, throughout Europe.

According to the Fremont, Calif.-based company, the ablation system provides surgeons with a minimally invasive approach to access the heart via two or three ports in the chest rather than a large incision or sternotomy. The catheter-based surgical probe is used with Cardima's Intellitemp radiofrequency (RF) energy management device to create cardiac lesions with temperature-regulated RF energy.

The company said that the probe increases lesion depth with irrigation and suction capabilities and aids in probe placement. Intellitemp allows electrode monitoring and temperature control, Cardima said.